We read with great interest the excellent article by Coriat et al. titled "Gastroenteropancreatic on Well‐Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement," published in ***The Oncologist*** \[[1](#onco12034-bib-0001){ref-type="ref"}\]. The authors reviewed in detail the epidemiology and made recommendations for the management of this new entity. They concluded that Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs), Grade 3 (NET G‐3), exist and differ from Poorly Differentiated (PD) GEP Neuroendocrine Carcinomas (NECs) in terms of prognosis.

Almost simultaneously, we published a multicenter Italian retrospective analysis of a large series of GEP NECs that was not referenced in this article \[[2](#onco12034-bib-0002){ref-type="ref"}\]. Our report identified an 18% prevalence of NET G3 (24/136) and confirmed that the category we named "NEC Type A"---defining a well‐differentiated (WD) tumor with a Ki‐67 index of 21%--55%---had a significantly different better survival than that seen with PD GEP NEC. Furthermore, our study revealed that not only morphology but also Ki‐67 index can affect survival. In addition, patients with neoplasms falling into the PD GEP NEC category and with a Ki‐67 index ≤55% had significantly longer survival than those with Ki‐67 index \>55%.

On the other hand, Coriat et al. suggested that a pancreatic primary may be more likely classified as a G3 NET, rather than as NEC, although the references for that statement did not provide information on the frequency of NET G3 at different sites. In our study, we observed that the prevalence of the pancreatic primary site was remarkably represented in 21% (29/136) of the total cohort; of those patients, 34.5% (10/29) showed WD morphology \[[2](#onco12034-bib-0002){ref-type="ref"}\].

Regarding therapy, Coriat et al. reported that everolimus and sunitinib were studied in two phase III randomized trials of G1‐G2 pancreatic NETs and concluded that "there is no validation of a targeted therapy except bevacizumab." However, given that NET G3 are well differentiated, as the vast majority of tumor populations included in the two aforementioned trials, everolimus and sunitinib should be considered among the possible therapeutic options. It cannot be excluded that some NET G3 were included in those studies, provided that Ki‐67 was unknown in tha main part of the tumors (on this basis the terms "G1" and "G2" should not be used). Furthermore, data on a limited number of patients with pancreatic NET G3 treated with everolimus were presented at the most recent European Neuroendocrine Tumor Society meeting (3).

Finally, we disagree with Coriat and colleagues\' statement that bevacizumab was validated in pancreatic NECs, based on the current evidence. We believe that biological therapies, such as molecular targeted agents and somatostatin receptor‐targeted treatments, should be prospectively investigated in patients with advanced NET G3 in comparison with platinum‐based chemotherapy, which is the current debatable standard treatment.
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